[Market Movement Analysis] Silexion Surges on September 17: Compliance-Based Stock Increase Proposal, Investor Meeting, and RNAi Anti-Cancer Progress

1. On September 16, the company submitted supplemental materials for the special shareholders' meeting. The authorized share capital increase proposal aims to help the company restore and maintain compliance with Nasdaq's shareholder equity requirements. Previously, the company appealed to the Nasdaq hearing panel regarding the delisting notice it received on August 18.
2. From September 14 to 16, company management participated in the H.C. Wainwright Global Investment Conference and held one-on-one meetings. The company is currently developing the SIL204 pan-KRAS RNA interference therapy, which is in phase 2/3 clinical trials for locally advanced pancreatic cancer.

(Disclaimer: This content is generated by AI technology that summarizes publicly available information and is for reference only. It does not constitute investment advice.)